• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 4, Issue 1
  3. Authors

Online ISSN: 2515-8260

Volume4, Issue1

Safety study of autologous adult bone marrow derived mesenchymal stromal cells in idiopathic pulmonary fibrosis - Pilot data

    Lakshmi Kiran Chelluria Upasna Upadhyaya Ravindra Nallagondab Sudhir Prasadb Mohammad Samiuddinb Rajat Mohantyb Chandrashekar Mallarpua Meenakshi Ponnanaa Sindhoora Rawulc Eswara Prasad Chelluric

European Journal of Molecular & Clinical Medicine, 2017, Volume 4, Issue 1, Pages 15-22

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Lung transplantation is the choice of therapy in severe cases of idiopathic pulmonary fibrosis (IPF) but is compounded with post-transplant complications. The paucity of deceased organ donations underlines the need for alternate approaches that improves the quality of life. Herein, we attempted to develop an autologous adult bone marrow derived mesenchymal stromal cell (BMSC) therapy via central line access, and evaluated the safety of a single dose (~13 × 106 cells/mL), in treating “no option” IPF. Method: The study included severe IPF subjects (n = 6) both male and female, aged 40–70 years of age with a forced vital capacity < 50%, diffusing capacity of lung for carbon monoxide (DLco) < 35% of predicted, and/or oxygen (SpO2) saturation < 88% on 6 min walk distance (6 MWD). BMSCs at passage 2 were suspended in 30.0 mL normal saline and dispensed through the central line route in a respiratory intensive care unit of Gleneagles Global Hospitals. The subjects were monitored for the first 24 h for serious adverse events and hemodynamic parameters. They were followed up periodically at intervals of 1, 4, and 9 months for safety and monitoring of adverse events, including secondary objectives of changes in pulmonary function test, DLco, 6 MWD, and quality of life as per the study protocol. Results: It was observed that central line infusions were well tolerated by all subjects. Furthermore, there was an improved quality of life. Conclusions: BMSC central line infusion in “no option” IPF cases provided an insight into the strategies in improving the quality of life for patient and thereby increasing the therapeutic window period for lung transplantation.
Keywords:
  • PDF (744 K)
  • XML
(2017). Safety study of autologous adult bone marrow derived mesenchymal stromal cells in idiopathic pulmonary fibrosis - Pilot data. European Journal of Molecular & Clinical Medicine, 4(1), 15-22.
Lakshmi Kiran Chelluria; Upasna Upadhyaya; Ravindra Nallagondab; Sudhir Prasadb; Mohammad Samiuddinb; Rajat Mohantyb; Chandrashekar Mallarpua; Meenakshi Ponnanaa; Sindhoora Rawulc; Eswara Prasad Chelluric. "Safety study of autologous adult bone marrow derived mesenchymal stromal cells in idiopathic pulmonary fibrosis - Pilot data". European Journal of Molecular & Clinical Medicine, 4, 1, 2017, 15-22.
(2017). 'Safety study of autologous adult bone marrow derived mesenchymal stromal cells in idiopathic pulmonary fibrosis - Pilot data', European Journal of Molecular & Clinical Medicine, 4(1), pp. 15-22.
Safety study of autologous adult bone marrow derived mesenchymal stromal cells in idiopathic pulmonary fibrosis - Pilot data. European Journal of Molecular & Clinical Medicine, 2017; 4(1): 15-22.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 44
  • PDF Download: 77
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus